ArticleSchizophrenia research. Cognition2022
Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia.
Article in Schizophrenia research. Cognition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Exploring the Relationship between Cognitive Performance, Performance-Based Functioning, and Everyday Functioning in People with Schizophrenia: a Systematic Literature Review.Schizophrenia bulletin · 2026Pooled it
- Feasibility and acceptability of a mobile intervention for patients with psychosis following psychiatric hospitalization: A pilot randomized controlled trial.Psychological services · 2025Trial
- The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia.Journal of clinical pharmacology · 2026Review
- Predictors for quality of life improvement in schizophrenia: a prospective study of patients in hospital-based rehabilitation programs.BMC psychiatry · 2026Article
- Neighborhood environmental deprivation predicts the generalized neurocognitive deficit in schizophrenia.Schizophrenia research · 2026Article
- Interrelationships among oxidative stress, niacin response, cognition, and symptoms in chronic schizophrenia: a case-control study.BMC psychiatry · 2025Observational
- Cognition before and after psychosis onset: A naturalistic study of change, heterogeneity, and prognosis.Schizophrenia research. Cognition · 2025Review
- Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study.BMC psychiatry · 2025Article
- Relationship between cognitive functions and serum neurotrophic factor levels in long-term hospitalized male patients with schizophrenia.BMC psychiatry · 2025Article
- Healthcare resource utilization burden associated with cognitive impairments identified through natural language processing among patients with schizophrenia in the United States.Schizophrenia (Heidelberg, Germany) · 2025Article
- Cognitive Correlates of Functional Disruption at Psychosis Onset: Unique Relevance of Visual Cognition.Journal of clinical medicine · 2025Article
- Cognitive symptoms in schizophrenia: an analysis of awareness, assessment, and management practices among psychiatrists and primary care physicians.Frontiers in psychiatry · 2025Article
- Quality of life and its predictors in first-episode schizophrenia and individuals at clinical high-risk for psychosis.BMC psychiatry · 2023Article
- Aberrant cortico-thalamo-cerebellar network interactions and their association with impaired cognitive functioning in patients with schizophrenia.Schizophrenia (Heidelberg, Germany) · 2023Article
- Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.Molecular psychiatry · 2023Review
- Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan.Therapeutic advances in psychopharmacology · 2022Article
- Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline.Frontiers in psychiatry · 2022Article
- Schizophrenia and dementia across the lifespan: epidemiological links, cognitive trajectories, and the pathophysiological interplay.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective was to investigate the association between cognitive impairment and healthcare resource utilization (HCRU) and quality of life (QoL) among patients with schizophrenia.
methodsData from the Adelphi Schizophrenia Disease Specific Programme™, a point-in-time survey of physicians and their patients, were collected in the United States between July-October 2019. Psychiatrists reported on patient cognitive function, HCRU, housing circumstances and employment status for their next 10 consulting adult patients with schizophrenia. Patients were classified as having no/mild or moderate/severe cognitive impairment and asked to complete a QoL questionnaire voluntarily. Multiple regression analysis estimated the association between severity of cognitive impairment and patient outcomes adjusting for patient demographics and clinical characteristics.
resultsPsychiatrists (n=124) reported on 651 and 484 patients with no/mild and moderate/severe cognitive impairment, respectively. Moderate/severe vs. no/mild cognitive impairment was associated with greater odds of hospitalization related to schizophrenia relapse within the last 12 months (adjusted odds ratio [aOR] [95% CI] = 2.23 [1.53-3.24]) and being unemployed due to disability (aOR = 2.39 [1.65-3.45]). Patients with moderate/severe vs. no/mild cognitive impairment had worse average QoL (EuroQoL 5-dimension [EQ-5D] Health Index: difference = -0.09 [-0.13 to -0.04]; EQ-5D Visual Analogue Scale: difference = -7.0 [-13.0 to -1.0]) and overall life satisfaction (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form: difference = -8.4 [-14.1 to -2.8]).
conclusionsModerate/severe cognitive impairment among patients with schizophrenia was associated with worse patient outcomes including greater risk of hospitalizations related to schizophrenia relapse. Treatment to improve cognitive function could benefit the large proportion of patients with schizophrenia who suffer from cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.